Core Insights - Chris Lau is an experienced investor and economist with 30 years in life science, technology, and dividend-growth income stocks [1] - He operates the DIY Value Investing group, focusing on undervalued stocks with catalysts for potential upside and dividend-income recommendations [1] Group 1: Flagship Products - Top DIY Picks feature undervalued stocks with upcoming catalysts that the market does not expect [2] - Dividend-income Champs include stocks with a long history of dividend growth, along with a printable calendar and quantitative scores [2] - DIY Community Picks are aimed at speculative allocations with positive momentum [2]

Group 1 - Chris Lau is an experienced investor and economist with 30 years in life science, technology, and dividend-growth income stocks [1] - He holds degrees in Microbiology and Economics, enhancing his analytical capabilities in investment [1] - Lau operates the DIY Value Investing group, focusing on undervalued stocks with catalysts for potential upside and dividend-income recommendations [1] Group 2 - The flagship products include Top DIY Picks, which are undervalued stocks with upcoming catalysts that the market does not expect [2] - Dividend-income Champs feature stocks with a long history of dividend growth, accompanied by a printable calendar and quantitative scores [2] - DIY Community Picks are aimed at speculative allocations with positive momentum [2]

Core Viewpoint - Cerrado Gold Inc. announces the resignation of Mr. Robert Campbell from its board of directors as he intends to retire, with management expressing gratitude for his contributions and wishing him well in retirement [1] Group 1: Company Overview - Cerrado Gold is a Toronto-based gold production, development, and exploration company, fully owning the Minera Don Nicolás and Las Calandrias mines in Argentina [2] - The company holds an 80% interest in the Lagoa Salgada VMS project in Portugal and is developing the Mont Sorcier Iron project in Canada, which it fully owns [2] Group 2: Operations in Argentina - In Argentina, Cerrado is enhancing asset value at the Minera Don Nicolás operation through operational optimization and increasing production at the Las Calandrias heap leach project [3] - An extensive exploration campaign is ongoing to unlock potential resources in the Deseado Masiff region [3] Group 3: Operations in Portugal - In Portugal, Cerrado is focused on the Lagoa Salgada VMS project, which is located on the Iberian Pyrite Belt and is characterized by high-grade polymetallic mineralization including zinc, copper, lead, tin, silver, and gold [4] - The project has significant exploration potential across its 7,209-hectare property and is strategically located 80 km from Lisbon, benefiting from excellent infrastructure [4] Group 4: Operations in Canada - Cerrado's Mont Sorcier Iron project has the potential to produce premium iron concentrate with low operating costs and a long mine life [5] - The high-grade and high-purity product supports the transition of steel producers to electric arc furnaces, aiding in the decarbonization of the industry [5]

Core Viewpoint - Certara, Inc. will release its financial results for Q3 2025 on November 6, 2025, after market close, followed by a conference call to discuss the results [1]. Company Overview - Certara is a global leader in biosimulation, utilizing software, technology, and services to enhance drug discovery and development [3]. - The company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries [3]. Event Details - A conference call will be held at 5:00 PM ET on the same day as the financial results release, and investors must register online to participate [1]. - It is recommended that investors register at least one day in advance [1]. - A live and archived webcast of the event will be available on Certara's website [2].

Core Insights - Cerrado Gold Inc. is accelerating its exploration program at the Minera Don Nicolas gold mine, increasing the scope from 20,000 metres to approximately 50,000 metres in 2026 by adding three additional drill rigs [1][2][4] Exploration and Development - The company plans to expedite assay completion by certifying its on-site lab, allowing for quicker turnaround times and issuing exploration results in batches for better clarity [2][4] - Operations at the Minera Don Nicolas site are performing well, with new investments in mining equipment leading to a delivery rate of 300,000 tonnes per month to the leach pad [3][4] - Underground development is progressing, with three access portals open and initial higher-grade underground ore being fed to the mill [3][4] Management Commentary - CEO Mark Brennan highlighted the significant potential of high-quality exploration targets and the decision to expand the drill program as a strategic move to enhance production and mine life [4] Company Overview - Cerrado Gold is a Toronto-based company focused on gold production, development, and exploration, owning the Minera Don Nicolas and Las Calandrias mines in Argentina, and holding interests in projects in Portugal and Canada [5][6][9]

Core Insights - The overall end market environment is subdued, but the company is focused on accelerating growth despite these conditions [1] - The company has made significant investments in sales and marketing over the past couple of years to build out its commercial organization [1] - The next phase of investment includes research and development (R&D), which is expected to continue into the next year [1] - Accelerated growth has been observed from the build-out of the commercial organization, particularly reflected in results from Tier 3 customers this year [1]

Core Insights - The overall end market environment is subdued, but the company is focused on accelerating growth despite these challenges [1] - The company has made significant investments in sales and marketing over the past couple of years to build out its commercial organization [1] - The next phase of investment includes research and development (R&D), which is expected to continue into the next year [1] - Accelerated growth has been observed from the build-out of the commercial organization, particularly reflected in results from Tier 3 customers [1]

Summary of Certara FY Conference Call - September 10, 2025 Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Health Technology and Biosimulation Key Points and Arguments Growth Strategy - Certara is focused on accelerating organic growth despite a subdued market environment, targeting mid-single-digit growth rates [4][5] - Investments in sales, marketing, and R&D are being made to enhance the commercial organization and software platforms [4][5] - New software enhancements, including Certara IQ (AI-enabled software for Quantitative Systems Pharmacology, QSP), are expected to drive growth [5][10] R&D and Product Development - Certara is addressing critical pain points in drug development, particularly the high failure rates of drug trials, by enhancing software capabilities [7] - The company has launched Certara Cloud, which has seen rapid adoption, particularly among large biopharma customers [11][12] - The tiered customer structure includes: - **Tier 1**: Large biopharma (50% of revenue) - **Tier 2**: Mid-sized companies (20% of revenue) - **Tier 3**: Biotechs (30% of revenue) [14][15] Market Dynamics - The funding environment for tier three customers remains challenging, but Certara has successfully targeted biotechs with funding potential [13][15] - The FDA's directive to shift away from animal testing is seen as a tailwind for Certara, enhancing customer discussions and driving demand for SIMCYP and QSP [24][34] Financial Performance - Certara expects an adjusted EBITDA margin of 30-32% for the year, consistent with previous performance [20] - The company is on track to meet its full-year plan despite some timing issues in software bookings for tier one customers [16][17] AI and Technology Integration - The acquisition of Vyasa has enabled Certara to integrate AI technology into its workflow and product offerings [25][26] - The co-author tool for regulatory writing has demonstrated a 40% efficiency improvement, appealing to regulatory customers [27] M&A and Strategic Review - Certara is actively engaged in a strategic review of its regulatory business, which has returned to growth with a 20-30% adjusted EBITDA margin [43][44] - The company is focused on software acquisitions to shift its revenue mix from services to software, aiming for a balanced profitability profile [45][46] Capital Allocation - Certara prioritizes R&D investments while also considering M&A opportunities and share buybacks, having authorized a $100 million share repurchase program [47][48] Additional Important Insights - Certara's longstanding relationship with the FDA provides a competitive advantage, as many FDA users are familiar with Certara's software [32][33] - The company is well-positioned to help biopharma clients find efficiencies across the drug development cycle, from discovery to submission [30][31] - The integration of Camaxon, a chem-informatics software company, is progressing well, with expectations to enhance margins and product offerings [40][41]

Company Overview - Certara is a leader in biosimulation software and services, focusing on revolutionizing drug discovery and development [1] - The company went public in 2020 and currently employs approximately 1,500 people globally [2] - Certara's services or software can be traced to 90% of all new drugs approved in the last decade, highlighting its significant impact on the pharmaceutical industry [3] Financial Performance - Certara is a profitable company with an EBITDA margin in the 30s [3] - The company's revenue is roughly split between software and services, with a 50% contribution from each segment [3] Industry Context - The drug development process is facing challenges, with nearly 90% of new medicines failing in interclinical trials, indicating a need for a new model in drug development [4]

Summary of Certara Conference Call Company Overview - **Company**: Certara - **Industry**: Biosimulation software and services for drug discovery and development - **Founded**: Went public in 2020 - **Employees**: Approximately 1,500 globally - **Financials**: Profitable with a 30% EBITDA margin, revenue split approximately 50% software and 50% services - **Impact**: 90% of new drugs approved in the last decade are linked to Certara's services or software [2][3] Core Insights - **Drug Development Challenges**: Nearly 90% of new medicines in clinical trials fail, leading to high costs in the pharmaceutical industry. The failure rate in large phase III trials is historically around 30% [3][4] - **Biosimulation Platform**: Certara's platform spans the entire drug development process, from discovery to approval, focusing on optimizing drug success rates and reducing costs [4][5] - **Simcyp Discovery Simulator**: A key product that predicts drug behavior in the human body, helping to avoid unnecessary clinical trials. Over 125 approved drugs have utilized this simulator [6][7] Market Dynamics - **Total Addressable Market (TAM)**: Biosimulation spending is currently only about 1.5% of global biopharma R&D, indicating significant growth potential [10][11] - **Regulatory Changes**: The FDA's recent announcement to reduce animal testing for monoclonal antibodies is seen as a positive development for Certara, potentially increasing demand for their modeling services [12][20] Product Development and Strategy - **Quantitative Systems Pharmacology (QSP)**: Certara is expanding its QSP offerings, which have seen increased adoption, particularly in monoclonal antibodies. The company aims to standardize QSP modeling through new software [16][18] - **Certara IQ**: A new software platform launching in the fall, designed to become an industry standard for QSP modeling, incorporating AI and regulatory-grade documentation [18][19] - **AI Integration**: Certara is leveraging AI to enhance productivity and model accuracy, while also developing a data infrastructure platform to support AI applications across client organizations [28][30][35] Financial Performance - **Current Growth**: Certara is experiencing 8% to 10% revenue growth, with software growing at 6% to 8%. The company aims to return to double-digit growth through new product offerings and market normalization [37][38] - **Renewals and Expansion**: Upcoming enterprise renewals are expected to drive additional spending, with a focus on expanding existing customer relationships [39][40] Additional Considerations - **Competition**: Certara has established a strong position in the market with a first-mover advantage, making it difficult for new entrants to compete effectively [26] - **Regulatory Acceptance**: The company’s software is recognized by regulators, which enhances its credibility and market position [26] This summary encapsulates the key points discussed during the conference call, highlighting Certara's strategic direction, market opportunities, and financial outlook.